Grants and Contributions:
Title:
Evaluation of Cytotoxicity and Effects on Gene Regulation of Selected Bile Acids in a Hepatocyte Model
Agreement Number:
903110
Agreement Value:
$29,801.00
Agreement Date:
Apr 2, 2018 - Mar 31, 2019
Description:
Selected compounds are being developed, for use in treatment of selected metabolic disorders. Nucleic acids extracted from cultured human liver cells will be analyzed to identify changes in the transcriptome in response to treatment with selected compounds.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6N 1C2
Reference Number:
172-2018-2019-Q2-903110
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
806657789
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 121 days.
Amendment Date
Nov 26, 2018
Recipient's Legal Name:
Qing Bile Therapeutics Inc.
Federal Riding Name:
Vancouver Quadra
Federal Riding Number:
59039
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: